Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP1 | P24666 | 2/20 | 0.39 |
| ▸ | ANPEP | P15144 | 3/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.36 |
| ▸ | MC4R | P32245 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.35 |
| ▸ | GNRHR | P30968 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2938027 | 0.85 | HRH3 (0.46) | ACP1ALDH1A1MAPTHTT | |
| SCHEMBL3797761 | 0.82 | GNRHR (0.36) | SIGMAR1LMNASMN1; SMN2GNRHR | |
| SCHEMBL2933001 | 0.77 | MC4R (0.54) | MC4R | |
| SCHEMBL6428663 | 0.75 | SMN1; SMN2 (0.43) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL13124134 | 0.72 | MC4R (0.57) | MC4R | |
| SCHEMBL2940093 | 0.71 | BACE1 (0.43) | SIGMAR1BACE1MC4R | |
| SCHEMBL27961380 | 0.71 | HRH3 (0.45) | ACP1BACE1 | |
| SCHEMBL2930807 | 0.71 | ACP1 (0.49) | ACP1ALDH1A1LMNAMAPTMC4R | |
| SCHEMBL13124129 | 0.70 | MC4R (0.55) | MC4R | |
| SCHEMBL17527302 | 0.70 | HRH3 (0.43) | ACP1BACE1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120316201-A1 | NOVEL BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AND USE THEREOF AS A MEDICAMENT | IPSEN PHARMA S.A.S. (FR) | 2012-12-13 | — | — | US | disclosed |
| US-8227485-B2 | Benzimidazole and imidazopyridine derivatives and use thereof as a medicament | IPSEN PHARMA S.A.S. (FR) | 2012-07-24 | — | — | US | disclosed |
| EP-1692114-B1 | NOVEL BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AND USE THEREOF AS A MEDICAMENT | IPSEN PHARMA (FR) | 2010-09-22 | — | — | EP | disclosed |
| US-20060281784-A1 | Novel benzimidazole and imidazopyridine derivatives and use thereof as a medicament | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) | 2006-12-14 | — | — | US | disclosed |
| EP-1692114-A1 | NOVEL BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AND USE THEREOF AS A MEDICAMENT | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005056533-A1 | NOVEL BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AND USE THEREOF AS A MEDICAMENT | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316201-A1 | NOVEL BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AND USE THEREOF AS A MEDICAMENT | MC4R, MC5R, MC1R | ACP1 4229/4885ANPEP 2973/4885SIGMAR1 450/4885 |
| US-20060281784-A1 | Novel benzimidazole and imidazopyridine derivatives and use thereof as a medicament | MC4R, MC5R, MC1R | ACP1 4104/4885ANPEP 2930/4885SIGMAR1 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.